Erectile Dysfunction

Group A £600; group B £680; group C £600 plus reasonable travel costs

About This clinical research study

Erectile dysfunction (ED) or erectile problems are terms used to describe when a man is unable to develop or sustain an erection, which can lead to difficulties in having sexual intercourse and low libido. 

IPED2015 (the study drug) is a potential new treatment for ED.  The study drug is a new compound which works by enhancing the effects of substances in the body such as serotonin and dopamine to help stimulate an erection.

The study will run over two months and you will need to visit the clinic seven times.  At four of the visits, you will take a dose of the medication, or a placebo (a pill with no active medication in it) and then be asked to fill in a sexual activity questionnaire.  Neither you nor the doctor will know whether you are taking the medication or the placebo.  People who take part in the study will be split into three groups. 

Group A will take the medication (or placebo) and fill in the questionnaire; Group B will take the medication (or placebo) and fill in the questionnaire and self-apply a Rigiscan device to measure the strength of their erection; Group C will take the medication (or placebo) and fill in the questionnaire and provide a semen sample.

Group A £600; group B £680; group C £600 plus reasonable travel costs

Clinics

Greater Manchester, Lancashire, Merseyside, South Staffordshire, South Yorkshire, Teesside and West Yorkshire

Therapy Area

Erectile Dysfunction

Gender and Age

Males aged between 18 - 59

A full description of the study will be given before you decide to take part, both over the phone and during an appointment at the MAC clinic. This will include you receiving the full patient information sheet (PIS). Your GP will also be notified of your participation.

If you contact us, it does not mean you have to decide at that point whether to participate.
If you do decide to participate you are free to withdraw at any time.

The clinic will adhere to current Government advice around social distancing and personal protective equipment (PPE) to protect site staffs and study participants. SARS-CoV-2 tests will be carried out, as required in addition to the completion of a SARS-CoV-2 symptom questionnaire prior to all clinic visits.

To take part in the study you need to have ED but no other physical or mental health problems and must not be taking any medications for your ED.  Further restrictions may apply depending on your medical history.

By participating in this clinical trial, you may be helping to contribute to the development of a new treatment that may help improve the quality of life for many people.

Reimbursement: Group A £600; group B £680; group C £600 plus reasonable travel costs

Key Inclusion Criteria

Key Exclusion Criteria

Other eligibility criteria will apply. Please contact MAC for more information.

Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.

ABOUT CLINICAL RESEARCH STUDIES

Clinical research studies are performed as a way of bringing about progress in medicine and research. Clinical research studies make it possible to scientifically assess the properties of a drug, to demonstrate the effectiveness and safety of a treatment or a medical device, or to learn more about a disease and methods to diagnose and monitor it.

If the study is successful, it may be an important step towards developing a promising new treatment.

MAC Clinical Research is conducting a trial to evaluate a potential new treatment for erectile dysfunction.

If you would like more information, please fill in the form below and we will be in touch…

Alternatively, please call our recruitment team on freephone 0800 633 5507.

Name*
Date Of Birth*
Hidden
Address*
Hidden
(You can enter any supporting information here)
Hidden
Hidden
Hidden
Hidden
Hidden
Data Privacy*
Data Privacy Statement

Know someone who may be interested in taking part? Share this page here:

Share on facebook
Facebook
Share on twitter
Twitter
Share on whatsapp
WhatsApp
Share on email
Email